Report Highlights

Toxicology Consulting in the U.S.: Market Overview

The United States holds roughly 40 percent of global toxicology consulting revenue, anchored by chemical manufacturers, pharmaceutical sponsors and federal regulators clustered along the Northeast corridor, the Research Triangle in North Carolina and the Washington, D.C. policy belt. Most engagements are driven by mandatory safety submissions under the Toxic Substances Control Act, FDA investigational new drug and new drug applications, and pesticide registrations under FIFRA rather than discretionary research, which makes revenue unusually resilient across economic cycles.

Structurally, the U.S. market departs from global norms in two ways. Consulting is regulation-led rather than laboratory-led, so advisory fees on risk evaluations frequently exceed the testing spend that follows. Roughly a third of demand also sits inside in-house toxicology teams at large pharmaceutical companies, which limits outsourced volume relative to Europe, where contract research organisations handle a larger share of regulatory work and agencies such as ECHA set the pace for hazard classification.

Growth Drivers in U.S. Toxicology Consulting

The Frank R. Lautenberg Chemical Safety for the 21st Century Act, which amended the Toxic Substances Control Act in 2016, requires EPA to complete risk evaluations of existing chemicals within three years, extendable by six months. EPA's first high-priority substances, including formaldehyde, 1,4-dioxane and asbestos, each demand exposure and hazard assessments that agency staff cannot complete alone, creating sustained outsourced demand for GLP-compliant consultancies.

The FDA Modernization Act 2.0, signed in December 2022, removed the statutory mandate for animal testing before human trials and opened the door to computational toxicology and organ-on-chip data. NIH's Complement-ARIE programme and FDA's ISTAND pilot fund validation of new approach methodologies, shifting consultant revenue toward integrated testing strategies. A large share of global IND filings originate in the United States, and demand for these services rises with each new modality, including cell and gene therapies.

Market Restraints and Entry Barriers

Entry requires GLP compliance under 40 CFR Part 792 for EPA-facing work and 21 CFR Part 58 for FDA submissions. Accreditation and inspection cycles typically take twelve to eighteen months before a new facility or subcontractor is accepted by sponsors, making time rather than capital the binding constraint. Senior engagements also require board-certified toxicologists, and the American Board of Toxicology credential remains scarce, pushing salaries upward. Firms without this talent pool cannot bid on complex TSCA risk evaluations.

Incumbent advantage is pronounced. Charles River Laboratories and Labcorp hold long-standing sponsor relationships and sell bundled laboratory-plus-advisory packages that smaller firms cannot match on price or timeline. Confidential business information protections under TSCA Section 14 also restrict how consultancies share manufacturer data across clients, limiting the data scale that drives advantage in exposure modelling and weakening new entrants' analytical position.

Market Opportunities in the U.S.

PFAS regulation offers the nearest-term opening. EPA's TSCA Section 8(a)(7) PFAS reporting rule and the April 2024 national primary drinking water standard, which sets limits of 4 parts per trillion for PFOA and PFOS, both generate exposure modelling and treatment-related toxicology demand. We estimate roughly USD 310 million of 2024 U.S. consulting spend links to PFAS work, with mid-sized firms holding the strongest position in state-level remediation advisory.

New approach methodology validation represents the second opening. Our estimate places U.S. demand for in silico modelling, read-across and organ-on-chip validation at roughly USD 180 million by 2030, with pharmaceutical sponsors seeking consultants who can draft FDA-acceptable credibility evidence. Firms that establish validated NAM workflows before 2027 will capture a disproportionate share of this segment as sponsors standardise vendor qualification.

Market at a Glance

Leading Market Participants

• Charles River Laboratories
• Labcorp Early Development
• Eurofins Scientific
• Intertek
• SGS
• Exponent
• Gradient
• Ramboll
• ICF
• WIL Research

Regulatory and Policy Environment

The Toxic Substances Control Act, as amended by the Lautenberg Act, is administered by EPA's Office of Chemical Safety and Pollution Prevention, which requires risk evaluations to be completed within three years of initiation, extendable by six months. Under TSCA Section 6, EPA must issue risk management rules within one year of finalising an evaluation, creating a rolling calendar that consultancies use to schedule staffing. Pesticide consulting falls under FIFRA, administered by the Office of Pesticide Programs.

FDA oversight rests on the Federal Food, Drug, and Cosmetic Act and 21 CFR Part 58 GLP rules, while ICH S-series guidelines shape nonclinical safety testing for pharmaceutical filings. EPA's September 2019 directive on reducing vertebrate animal testing sets a target to reduce mammalian studies by 30 percent by 2025 and eliminate them by 2035, requiring consultants to hold NAM capability well before that deadline.

Long-Term Outlook for U.S. Toxicology Consulting

By 2032 the U.S. toxicology consulting market is projected to reach USD 2.34 billion, with regulatory-led work growing fastest as TSCA risk evaluations, PFAS rules and drinking water standards mature. Consultancies holding GLP accreditation, computational toxicology platforms and state-level remediation expertise will hold the leading positions, while generalist firms dependent on single-sponsor contracts face consolidation pressure.

The competitive map will shift toward a two-tier structure. Global contract research organisations will defend laboratory volume, while specialist advisory firms take the regulatory and litigation work that requires interpretation of agency data. Acquisitions of regional consultancies by larger testing groups will accelerate, and NAM validation will become a standard line item in pharmaceutical IND budgets by the early 2030s.